BYSI: BeyondSpring Inc. Stocks News on December 18, 2024

BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting

BYSI

GlobeNewswire

a month ago

BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting

BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024

BYSI

GlobeNewswire

3 months ago

BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024

BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024

BYSI

GlobeNewswire

3 months ago

BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024

BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respiratory Medicine

BYSI

GlobeNewswire

3 months ago

BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respiratory Medicine

BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin

BYSI

GlobeNewswire

3 months ago

BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin

BYSI

Simply Wall St.

4 months ago

Is BeyondSpring (NASDAQ:BYSI) In A Good Position To Invest In Growth?

SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications

BYSI

GlobeNewswire

4 months ago

SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications

BYSI

MT Newswires

6 months ago

BeyondSpring Raises $3 Million via Stock Sale

Italian energy company targets Britain for fleet of 20 mini-nukes

BYSI

The Telegraph

6 months ago

Italian energy company targets Britain for fleet of 20 mini-nukes

It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend

BYSI

Simply Wall St.

6 months ago

It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend

Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?

BYSI

Simply Wall St.

6 months ago

Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?

Don't Buy Banc of California, Inc. (NYSE:BANC) For Its Next Dividend Without Doing These Checks

BYSI

Simply Wall St.

6 months ago

Don't Buy Banc of California, Inc. (NYSE:BANC) For Its Next Dividend Without Doing These Checks

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow

BYSI

Motley Fool

6 months ago

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow

Should You Be Adding Mueller Water Products (NYSE:MWA) To Your Watchlist Today?

BYSI

Simply Wall St.

6 months ago

Should You Be Adding Mueller Water Products (NYSE:MWA) To Your Watchlist Today?

Seoul resumes loudspeaker propaganda against North

BYSI

AFP

6 months ago

Seoul resumes loudspeaker propaganda against North

Graham Full Year 2024 Earnings: EPS: US$0.42 (vs US$0.035 in FY 2023)

BYSI

Simply Wall St.

6 months ago

Graham Full Year 2024 Earnings: EPS: US$0.42 (vs US$0.035 in FY 2023)

BYSI

Simply Wall St.

7 months ago

BeyondSpring (NASDAQ:BYSI) shareholders have earned a 141% return over the last year

BYSI

MT Newswires

7 months ago

Top Premarket Decliners

BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

BYSI

GlobeNewswire

7 months ago

BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

BYSI

GlobeNewswire

8 months ago

BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results

BYSI

GlobeNewswire

8 months ago

BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results

BeyondSpring Files 2023 Annual Report on Form 20-F

BYSI

GlobeNewswire

8 months ago

BeyondSpring Files 2023 Annual Report on Form 20-F

BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer

BYSI

GlobeNewswire

9 months ago

BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer

BYSI

Simply Wall St.

9 months ago

Retail investors invested in BeyondSpring Inc. (NASDAQ:BYSI) up 125% last week, insiders too were rewarded

BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements

BYSI

GlobeNewswire

10 months ago

BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements

BYSI

GlobeNewswire

a year ago

Comscore announces new US patent for livestream contextual intelligence technology

Alithya to consolidate trading on the TSX and announces voluntary delisting from Nasdaq

BYSI

CNW Group

a year ago

Alithya to consolidate trading on the TSX and announces voluntary delisting from Nasdaq

BYSI

GlobeNewswire

a year ago

Comscore and Nexstar Reach Multi-Year Agreement for Linear and Cross-Platform Audience Measurement

Atossa Therapeutics, Inc. (NASDAQ:ATOS): Is Breakeven Near?

BYSI

Simply Wall St.

a year ago

Atossa Therapeutics, Inc. (NASDAQ:ATOS): Is Breakeven Near?

Is Flexsteel Industries (FLXS) Stock Outpacing Its Consumer Discretionary Peers This Year?

BYSI

Zacks

a year ago

Is Flexsteel Industries (FLXS) Stock Outpacing Its Consumer Discretionary Peers This Year?

Analysts Expect comScore, Inc. (NASDAQ:SCOR) To Breakeven Soon

BYSI

Simply Wall St.

a year ago

Analysts Expect comScore, Inc. (NASDAQ:SCOR) To Breakeven Soon

Sidoti Events, LLC's Virtual January Micro-Cap Conference

BYSI

ACCESSWIRE

a year ago

Sidoti Events, LLC's Virtual January Micro-Cap Conference

EV Roundup: TSLA's Berlin Output Halt & HMC's New EV Series Hog the Limelight

BYSI

Zacks

a year ago

EV Roundup: TSLA's Berlin Output Halt & HMC's New EV Series Hog the Limelight

BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K

BYSI

GlobeNewswire

a year ago

BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K

Electrovaya Announces Date for Q4 FY-2023 and FY-2023 Financial Results and Conference Call

BYSI

ACCESSWIRE

a year ago

Electrovaya Announces Date for Q4 FY-2023 and FY-2023 Financial Results and Conference Call

BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

BYSI

GlobeNewswire

a year ago

BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

Elutia Submits CanGarooRM® Antibiotic-Eluting Biomatrix for FDA Clearance

BYSI

GlobeNewswire

a year ago

Elutia Submits CanGarooRM® Antibiotic-Eluting Biomatrix for FDA Clearance

Taylor Devices (NASDAQ:TAYD) Shareholders Will Want The ROCE Trajectory To Continue

BYSI

Simply Wall St.

a year ago

Taylor Devices (NASDAQ:TAYD) Shareholders Will Want The ROCE Trajectory To Continue

Travelzoo Introduces Membership Fee for New Members Beginning January 1, 2024

BYSI

PR Newswire

a year ago

Travelzoo Introduces Membership Fee for New Members Beginning January 1, 2024

Brainsway Ltd. Sponsored ADR (BWAY) Is a Great Choice for 'Trend' Investors, Here's Why

BYSI

Zacks

a year ago

Brainsway Ltd. Sponsored ADR (BWAY) Is a Great Choice for 'Trend' Investors, Here's Why

Frequency Electronics, Inc. (NASDAQ:FEIM) Q2 2024 Earnings Call Transcript

BYSI

Insider Monkey

a year ago

Frequency Electronics, Inc. (NASDAQ:FEIM) Q2 2024 Earnings Call Transcript

BYSI

Zacks

a year ago

New Strong Buy Stocks for December 13th

BYSI

Thomson Reuters StreetEvents

a year ago

Q4 2023 Inotiv Inc Earnings Call

Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2023 and Provides Business Update

BYSI

GlobeNewswire

a year ago

Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2023 and Provides Business Update

FiscalNote Announces Strategic Commercial Partnership to Accelerate Company’s Global AI Co-pilot Program

BYSI

Business Wire

a year ago

FiscalNote Announces Strategic Commercial Partnership to Accelerate Company’s Global AI Co-pilot Program

Just Four Days Till First Savings Financial Group, Inc. (NASDAQ:FSFG) Will Be Trading Ex-Dividend

BYSI

Simply Wall St.

a year ago

Just Four Days Till First Savings Financial Group, Inc. (NASDAQ:FSFG) Will Be Trading Ex-Dividend

Are You Looking for a High-Growth Dividend Stock?

BYSI

Zacks

a year ago

Are You Looking for a High-Growth Dividend Stock?

BYSI

Zacks

a year ago

Zacks Industry Outlook Highlights Logitech, LG Display and TransAct Technologies

Research Solutions Announces Acquisition of scite

BYSI

PR Newswire

a year ago

Research Solutions Announces Acquisition of scite

Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

BYSI

GlobeNewswire

a year ago

Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

BYSI

Associated Press Finance

a year ago

Allot Communications: Q3 Earnings Snapshot

Allot Announces Q3 2023 Financial Results

BYSI

PR Newswire

a year ago

Allot Announces Q3 2023 Financial Results

Nicholas Financial Insiders Are Down US$31k But Regain Some Losses

BYSI

Simply Wall St.

a year ago

Nicholas Financial Insiders Are Down US$31k But Regain Some Losses

BYSI

Associated Press Finance

a year ago

PDS Biotechnology: Q3 Earnings Snapshot

UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

BYSI

GlobeNewswire

a year ago

UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q3 2023 Earnings Call Transcript

BYSI

Insider Monkey

a year ago

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q3 2023 Earnings Call Transcript

Forian Inc. (NASDAQ:FORA) Q3 2023 Earnings Call Transcript

BYSI

Insider Monkey

a year ago

Forian Inc. (NASDAQ:FORA) Q3 2023 Earnings Call Transcript

Research Solutions to Participate in Pair of Investor Conferences

BYSI

PR Newswire

a year ago

Research Solutions to Participate in Pair of Investor Conferences

Hycroft Mining Announces 1-For-10 Reverse Stock Split

BYSI

PR Newswire

a year ago

Hycroft Mining Announces 1-For-10 Reverse Stock Split

Clarus Corporation (NASDAQ:CLAR) Q3 2023 Earnings Call Transcript

BYSI

Insider Monkey

a year ago

Clarus Corporation (NASDAQ:CLAR) Q3 2023 Earnings Call Transcript

$BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitors$